Santiago Moreno

HEOR director at Novartis

Santiago Moreno is a prominent figure in the field of Health Economics and Outcomes Research (HEOR), currently serving as the Global Health Economics and Outcome Research Director at Novartis, a position he has held since November 2019. Based in Basel, Switzerland, he has over 10 years of experience in HEOR and Health Technology Assessment (HTA) across both the public and private sectors.1 2

Professional Background

Current Role: At Novartis, Santiago leads the global HEOR strategy for key products, including the blockbuster drug Cosentyx®, focusing on both market access and evidence generation to support pricing and reimbursement negotiations.2
Previous Experience:
- Global Senior HEOR Manager at Servier (2018-2019), where he managed HEOR for oncology products.
- Region Europe HEOR Manager at Novartis (2016-2018), responsible for market access strategies across Europe.
- Global Health Economist at Roche (2012-2016), contributing to various health economic evaluations.1 2

Education

Santiago holds a Doctor of Philosophy in Accounting from the University of Leicester and has completed studies at the University of Cambridge. He also earned a Bachelor of Science in Business from Liverpool John Moores University.1

Skills and Expertise

Santiago's expertise encompasses a wide range of areas within health economics, including:

Health Technology Assessment (HTA)
Market Access Strategies
Clinical Trials and Research
Pharmacoeconomics
Patient-Reported Outcomes (PRO) strategies

His contributions to the field include leading significant submissions to health technology assessment bodies, which have influenced policy proposals related to HTA and payer negotiations.2

Overall, Santiago Moreno is recognized for his leadership in HEOR, particularly in developing strategies that align clinical evidence with market access needs in the pharmaceutical industry.